Macrocyclic Peptides Discovered to Specifically Target Cancer-Associated RhoA Mutation
Background
The small GTPase RhoA is a crucial regulator of cell signaling, controlling processes like cell migration, adhesion, and proliferation. Mutations in RhoA, such as G17V, are frequently found in various cancers, including diffuse gastric cancer and melanoma, where they contribute to tumor progression and metastasis by altering RhoA's activity. Current therapeutic approaches often lack the specificity to target these mutant forms without affecting healthy cells. This study aimed to identify and characterize novel macrocyclic peptides that specifically bind to and inhibit the oncogenic RhoA G17V mutant, offering a potential pathway for highly targeted cancer therapies.
Results
The phage display screen successfully identified several macrocyclic peptides with high specificity for RhoA G17V. The lead candidate, RHO-Target-1 (RT-1), demonstrated a remarkable 32-fold higher binding affinity for RhoA G17V compared to wild-type RhoA in SPR (Surface Plasmon Resonance) assays, with a dissociation constant (Kd) of 12.5 nM. > Computational modeling revealed that RT-1 binds to a unique, previously uncharacterized allosteric pocket on RhoA G17V, inducing a conformational change that significantly impairs its interaction with downstream effector proteins, leading to a 65% reduction in its intrinsic GTPase activity in vitro (p<0.001). Further in vitro cellular assays showed that treatment with RT-1 at a concentration of 100 nM reduced the migratory capacity of RhoA G17V-mutant gastric cancer cells by 48% compared to vehicle-treated controls (p<0.0001), while having minimal effect on wild-type RhoA-expressing cells. This selective inhibition highlights RT-1's potential as a precise therapeutic agent.
Why It Matters
This research represents a significant advancement by identifying a novel class of macrocyclic peptides that specifically target the oncogenic RhoA G17V mutation. The high specificity and potent in vitro inhibitory activity of RHO-Target-1 suggest a promising strategy for developing highly selective anti-cancer therapeutics that could minimize off-target effects. These findings lay a crucial foundation for the development of precision medicines for cancers driven by specific RhoA mutations. Future research will focus on optimizing RT-1 for in vivo stability and bioavailability, followed by rigorous preclinical testing in animal models of RhoA G17V-driven cancers, potentially paving the way for Phase I human clinical trials.